PPCB · Propanc Biopharma, Inc. · Metrics
$0.85
-0.07 (-7.71%)
At close · Sep 14
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“It is management's opinion that these conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of at least twelve months from the issue date of this Quarterly Report.”View the 10-Q filed May 14, 2026
Market Cap
$2.10M
Shares
2.28M
PPCB metrics
40 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$0.85
Market cap
$2.10M
Price action
20 metricsPrice change (1W)
-8.8%
Price change (30D)
-19.9%
Price change (3M)
-59.4%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
272.8%
Annualized volatility (3M)
258.0%
Beta
—
RSI (14D)
42.1
Price vs SMA 50
-29.1%
Price vs SMA 200
—
Avg volume (3M)
2.75M
Relative volume
0.1
Average dollar volume
$5.51M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
2.28M
Valuation
12 metricsP / E (TTM)
0.0
Trailing earnings · reciprocal yield 176,112.9%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.2
reciprocal yield 468.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-875.0%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$18.37M
Net income (TTM)
−$18.36M
Trailing 12 months
Diluted EPS (TTM)
$1,622.00
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+418.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-186.8%
Return on assets
-128.1%
Debt / equity
—
Current ratio
2.4
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
2.4
Interest coverage
-27.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$93,241
Total assets
$14.33M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$4.17M
Capital expenditures (TTM)
—
R&D (TTM)
$303,344
SG&A (TTM)
—
Stock compensation (TTM)
$10.39M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
4
13F filer change QoQ
-2
Institutional ownership
2.1%
Short interest
3 metricsShort interest
14.7%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
62 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged